United States: DOJ's $678 Million Novartis Settlement For False Claims Act And Anti-Kickback Statute Violations—Changing Big Pharma's Expectations For Compliance Programs

Roopa Chakkappan authored an article titled, "DOJ's $678 Million Novartis Settlement for False Claims Act and Anti-Kickback Statute Violations—Changing Big Pharma's Expectations for Compliance Programs," which was posted on the American Health Law Association's (AHLA) website.  Click here to read the full article.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.